Sponsored by:
Title: Weekly GLP-1s in the Real World: Long-Term Use, Microdosing and the Peptide Problem
Speaker: A/Prof Samantha Hocking
Weekly GLP-1 receptor agonists have changed obesity and metabolic care, but questions from patients and clinicians keep growing. The case for long-term treatment will be set out, given the weight regain and loss of health benefits when therapy stops, and the main safety considerations will be reviewed, including pancreatitis, NAION and changes in body composition. What "microdosing" really means will be examined, along with whether lower doses that suffice for weight loss also preserve weight-independent benefits. The unregulated peptide market will also be addressed, including what patients are actually taking and how clinicians can discuss it constructively and without judgement.